Latest Earnings Results: Q2 '26
Estimated EPS
-$2.04
Reported EPS
-$3.06
Surprise
-49.81%
Estimated Rev
$1.77M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$3.06 down -133.59% YoY • Revolution Medicines is updating its full year 2026 GAAP operating expense guidance to a range of $2.1 to $2.2 billion, which includes estimated non-cash stock-based compensation expense of $270 to $290 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$2.43 | -- | -- | N/A |
Q2 '26 | -$2.04 | -$3.06 | -49.81% | MISSED |
Q1 '26 | -$1.84 | -$2.29 | -24.75% | MISSED |
Q4 '25 | -$1.58 | -$1.86 | -17.63% | MISSED |
Q3 '25 | -$1.42 | -$1.61 | -13.29% | MISSED |